AVP AVPI

  1. All
  2. Commentary
  3. Headlines
    1. All Pop And No Sizzle Or Is Avanir Going Higher From Here?

      Headlines

      Wed, 17 Sep 2014

      previous session at 6.74 and closing on the 15th at 12.40 on the announcement of a successful phase-II trial of their drug AVP -923 , which has until now been used to treat patients with pseudobulbar affect under the brand name Neudexta, for use in patients

    2. Proft taking after Avanir up move

      Headlines

      Tue, 16 Sep 2014

      Avanir Pharmaceuticals (NASDAQ: AVNR ) is off 6% premarket on robust volume as traders begin to take profits from yesterday's ultra-bullish 85% jump on turnover of ~89M shares in response to positive Phase 2 trial results for AVP -923. Post your comment!

    3. Concert Pharma rides Avanir's coattails

      Headlines

      Mon, 15 Sep 2014

      pop after it reported positive Phase 2 results for AVP -923. Concert's license agreement with Avanir pertains ..... modified dextromethorphan (d-DM) which is what AVP -786 is based on. AVP -923 is a combination of dextromethorphan and quinidine

    4. Avanir skyrockets premarket on trial results

      Headlines

      Mon, 15 Sep 2014

      response to its announcement of positive results from its Phase 2 trial evaluating AVP -923 for the treatment of agitation in patients with Alzheimer's disease. AVP -923 achieved the primary endpoint of a statistically significant reduction in

    5. Herbalife Field Report: Nutrition Clubs

      Headlines

      Sat, 13 Sep 2014

      By Rogier van Vlissingen : Herbalife (NYSE: HLF ) continues to amaze. The stock has been sliding on low volumes for quite a while, then we had an acceleration in volume for a few days and a continuing slide, with two 52-week lows posted on successive days. At the open on 9/11, it went up a bit, ...

    6. Avanir clinical trial triggers milestone payment to Concert Pharma

      Headlines

      Tue, 26 Aug 2014

      The initiation of Avanir Pharmaceuticals' ( AVNR +2% ) AVP -786 clinical trial for MDD triggers a $2M milestone payment to Concert Pharmaceuticals ( CNCE +5.1% ) as part of their license agreement for deuterium-modified dextromethorphan compounds. Post your comment!

    7. Avanir commences clinical trial for MDD med

      Headlines

      Tue, 26 Aug 2014

      initiates a Phase 2 study to evaluate the safety, tolerability and efficacy of AVP -786 for the adjunctive treatment of major depressive disorder (MDD). AVP -786 is a combination of deuterium-modified dextromethorphan and ultra-low dose

    8. From Barron’s, June 16, 2014 (Part 2)

      Commentary

      Sat, 14 Jun 2014

      H2. Gabelli: KINVA .sw, IFF, IPG, CHMT, WFT, MSG Gross: BBN, PDI, PFF Black: SMCI, PDCE Rogers [Brian]: AMAT, AVP , CNX, NEM, CVC, PRMSX Zulauf: None except bonds ; negative views on easing, markets, EMs, China . Japan rally by yearend

    9. From Barron’s, June 16, 2014 (Part 1)

      Commentary

      Sat, 14 Jun 2014

      H2. Gabelli: KINVA .sw, IFF, IPG, CHMT, WFT, MSG Gross: BBN, PDI, PFF Black: SMCI, PDCE Rogers [Brian]: AMAT, AVP , CNX, NEM, CVC, PRMSX Zulauf: None except bonds ; negative views on easing, markets, EMs, China . Japan rally by yearend

    10. From Barron’s, May 26, 2014 (Part 1)

      Commentary

      Sat, 24 May 2014

      rapidly. Korean companies [Amorepacific, Cosmax] have gained market share at the expense of Japanese [Shiseido] and US [ AVP ] companies. Pg M9, Yields : Junk bonds are overvalued [yield 5.15%; spread 378 bps; price 104.9] but investors keep

    « Prev12Next »
    Content Partners